Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes
NCT ID: NCT02136589
Last Updated: 2014-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2008-09-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
IOP reduction is caused by direct FP receptor stimulation, but the cause of hyperemia is not clarified.
Because FP receptor stimulation induce intrinsic production of PGs, hyperemia or IOP reduction may be due to secondary induced PGs.
Thus, pretreatment with NSAID may affect the PG-analogue induced hyperemia or IOP reduction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients
NCT00308945
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
NCT01658839
Ocular Surface Disease and IOP Monitoring With Travoprost Without Conservatives
NCT05319470
Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost
NCT00637130
Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects
NCT00810381
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dicrofenac
dicrofenac and travoprost
dicrofenac drop 3 times a day travoprost 0.005% once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dicrofenac and travoprost
dicrofenac drop 3 times a day travoprost 0.005% once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. not applicable for IOP level
3. not wearing contact lenses
4. not applicable for the presence of the ocular surface diseases in case the treatment was not needed
Exclusion Criteria
2. the eyes with the history of trauma, intraocular surgery, or Laser surgery within 6 months
3. the eyes with difficulty for the measurement of IOP with the applanation tonometer
4. the subjects with the allergy for PG-analogues or benzalkonium chloride
5. the subjects using the eyedrops excluding those in this study
6. the subjects treated with oral carbonic anhydrase inhibitor
7. the subject with Sjogren syndrome
8. the subjects who can not drop periodically
9. the subjects with the advanced glaucoma or the terminal stage of glaucoma
10. the subjects with the severe ocular complications
20 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tokyo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Makoto Aihara
Associate Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS-097
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.